Social inhibition

Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, March 9, 2021
Research, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Branches of biology, Muscular dystrophy, Myostatin, Cash and cash equivalents, Social inhibition

Scholar Rock is evaluating multiple other diseases for which the selective inhibition of the activation of myostatin may offer therapeutic benefit.

Key Points: 
  • Scholar Rock is evaluating multiple other diseases for which the selective inhibition of the activation of myostatin may offer therapeutic benefit.
  • As of December 31, 2020, Scholar Rock had cash, cash equivalents, and marketable securities of approximately $341.0 million.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

BELLUS Health Reports Year 2020 Financial Results and Business Highlights

Retrieved on: 
Thursday, February 25, 2021
Health, Managed care, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Communication, Forward-looking statement, Irritation, Chronic cough, Social inhibition, Cough, Articles, Medical specialties, BLU-5937, BELLUS Health (

BELLUS Health is exploring how P2X3 activation can contribute to irritation and pain, and whether inhibition of P2X3 receptors can help treat these afferent hypersensitization-related disorders.

Key Points: 
  • BELLUS Health is exploring how P2X3 activation can contribute to irritation and pain, and whether inhibition of P2X3 receptors can help treat these afferent hypersensitization-related disorders.
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.
  • Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements.
  • BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct.

Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs

Retrieved on: 
Monday, November 23, 2020
Psychiatric diagnosis, Psychiatry, Psychology, Mind, Abnormal psychology, Anxiety, Emotions, Social inhibition, Anxiety disorders

The grant is expected to fund 50% of expenses related to preclinical research investigating ART26.12 as a potential treatment for anxiety disorders.

Key Points: 
  • The grant is expected to fund 50% of expenses related to preclinical research investigating ART26.12 as a potential treatment for anxiety disorders.
  • In addition to anxiety disorders, the company plans to develop ART26.12 for the treatment of cancer, inflammation, and pain.
  • Inhibition of FABP5 has been shown to lead to higher levels of AEA and may have significant potential in treating anxiety.
  • Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving challenges with research solutions from academic institutions.

Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference

Retrieved on: 
Monday, May 18, 2020
Oncology, Mental health, Health, FDA, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Muscular dystrophy, Myostatin, Social inhibition, Topaz, SRK-015, Scholar Rock

Details for the SRK-015 TOPAZ presentation at the conference are as follows:

Key Points: 
  • Details for the SRK-015 TOPAZ presentation at the conference are as follows:
    AAN Science Highlights virtual platform: Virtual presentation will be available starting May 18, 2020.
  • Scholar Rock believes the inhibition of the activation of myostatin with SRK-015 may promote a clinically meaningful improvement in motor function.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

Scholar Rock Presents Data for SRK-015 at the Muscular Dystrophy Association Clinical and Scientific Conference

Retrieved on: 
Tuesday, March 24, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, Muscular dystrophy, Myostatin, Social inhibition

Scholar Rock believes the inhibition of the activation of myostatin with SRK-015 may promote a clinically meaningful increase in muscle strength.

Key Points: 
  • Scholar Rock believes the inhibition of the activation of myostatin with SRK-015 may promote a clinically meaningful increase in muscle strength.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.
  • All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

CHILD-BRIGHT Network and Ehave Start Enrollment for Cognitive Rehabilitation Trial for Children with ADHD, Autism, and Congenital Heart Disease

Retrieved on: 
Thursday, June 28, 2018
Psychiatry, Psychology, Shyness, Social inhibition, Mental disorder

OAKVILLE, Ontario, June 28, 2018 /PRNewswire/ --The CHILD-BRIGHT Network , a Canadian patient-oriented research network focussed on pediatric brain-based developmental disorders, and Ehave, Inc .

Key Points: 
  • OAKVILLE, Ontario, June 28, 2018 /PRNewswire/ --The CHILD-BRIGHT Network , a Canadian patient-oriented research network focussed on pediatric brain-based developmental disorders, and Ehave, Inc .
  • Children will play a series of games that target response inhibition time and working memory.
  • Via in-clinic assessments at the start and end of the trial, and again 3 months later, the research team will measure improvements in executive functions, attention and self-regulation.
  • "The trial with the CHILD-BRIGHT Network is an important step to validate the treatment impact of Mega Team with high-quality clinical rigour.